Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Generium to begin clinical drug trial for idiopathic thrombocytopenic purpura
- By Newsdesk
- Moscow
- May 23, 2023
Generium, a domestic biotechnological drug development company, will conduct clinical trials (CT) in Moscow of a drug for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). The capital has allocated 6 million rubles for the organisation of tests as a support for the manufacturer, according to Anastasia Rakova, vice-mayor of the city.
The development will be tested at two leading Moscow clinics: MKNTS im. A. S. Loginov and GKB im. S. P. Botkin, which specialise in the treatment of patients with haematological diseases. The drug from "Generium" is a biosimilar to the foreign "Enplate" from Amgen that can be imported.
ITP is an autoimmune haematological disease characterised by an increase in platelet destruction during blood clotting processes. Disability is highly likely in the absence of treatment.
Previously, Moscow Mayor Sergei Sobyanin stated that over 500 preclinical and clinical drug trials have been conducted in the capital over the last three years, and that the city has received applications for trials of 16 drugs from seven companies since September 2022. Nine developments have already been assigned study sites.